

MODULE 2: Diabetic Kidney Disease – A Protean Dilemma

George Bakris, MD, MA

Program Description

Fewer people with diabetes today are progressing to dialysis compared to 30 years. Moreover, the rate of annual decline in kidney function is slower by 70% compared to 1980. Lastly, newer classes of drugs shown to lower glucose have also shown a further slowing of CKD progression in diabetes.

Learning Objectives

At the conclusion of this activity, participants should be able to:

- Describe the latest statistics regarding diabetic kidney disease progression.
- Identify newer guideline approaches to achieve BP and glucose control to slow CKD progression.

Bibliographic Sources to Allow for Further Study

- ADA Clinical Practice Guidelines-Diabetes Care 2019 (Suppl1).
- Dojki, F. K. and Bakris GL. Blood Pressure Control and Cardiovascular/Renal Outcomes. *Endocrinol Metab Clin North Am* 2018; 47(1): 175-184.

Accreditation

The University of Rochester School of Medicine and Dentistry is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Certification

The University of Rochester School of Medicine and Dentistry designates this enduring material for a maximum of *0.75 AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

No commercial funds have been received to support this educational activity.

Planning Committee / Speaker Disclosures

The following speakers have disclosed financial interests/arrangements or affiliations with organization(s) that could be perceived as a real or apparent conflict of interest in the context of the subject of their presentation(s). Only the current arrangements/interests are included.

*Planning Committee Members

George Bakris, MD

Speaker declared Steering Committee for Janssen and Novo Nordisk and Principal Investigator for Bayer of Diabetic Nephropathy Trials with all monies going to the University of Chicago Medicine. Also Steering Committee for Vascular Dynamics for Resistant Hypertension trial with all monies going to the University of Chicago Medicine. Also declared Consultant for Merck Global

Tamara Eis, MS, RN-BC*

Planner declared that no financial interest or relationship exists

Stephen Hammes, MD, PhD*

Planner declared that no financial interest or relationship exists

Heidi Kipp, NP*

Planner declared that no financial interest or relationship exists

Steven Wittlin, MD*

Planner declared Consultant for Sensionics and Speakers' Bureau for Medtronic Diabetes

The Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support require that presentations are free of commercial bias and that any information regarding commercial products/services be based on scientific methods generally accepted by the medical community. When discussing therapeutic options, speakers are requested to use only generic names. If they use a trade name, then those of several companies should be used. If a presentation includes discussion of any unlabeled or investigational use of a commercial product, speakers are required to disclose this to the participants.